Dexcom

Explainers

Plain-language answers to the questions people ask about Dexcom, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

• What is Dexcom Stelo?

  Dexcom Stelo is the first OTC continuous glucose monitor (CGM) for non-diabetic consumers, cleared via FDA De Novo pathway March 2024. Stelo carries Dexcom's medical-sensor heritage + a Vertex AI / Gemini generative AI insight layer that distinguishes it from Abbott Lingo's adaptive algorithmic AI substance. Pricing: ~$89 per 2-week sensor + biweekly subscription model. Per DEPLOY's biometric cluster framework, Stelo is the cohort's medical-sensor-with-AI-insight bridge cell anchor: passes biometric boundary test via genuine generative AI substance (not adaptive algorithmic) per Agent A Wave 2 + Wave 3 ingest.

Current leadership (3)

• Jacob Leach Chairman, President & CEOreported, not verified
• John Burd Co-founderreported, not verified
• Scott Glenn Co-founderreported, not verified

Founders (2)

• John Burdcofounderno longer at company
• Scott Glenncofounderno longer at company

Safety record

No incidents on record for Dexcom.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Operated deployments (1)

• SteloGlobal

Operator customers (1)

• Dexcom1 deployment

Peer companies

• Samsung Electronics4 models
• Butterfly Network2 models
• Abbott1 model
• Apple1 model
• Circular1 model
• Fitbit1 model

Financial state

Reporting basis

aggregator_estimate

Lifecycle stage

mature

Counterparty risk class

low

Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.

Funding rounds (1)

• IPO2005-01-01

  $50M(reported)

Regulatory filings (1)

• K234070fda 510k · us_fdacleared2023-12-22

  Linked models: Stelo

Sources (3)

1. https://investors.dexcom.com/news/news-details/2024/Stelo-by-Dexcom-First-Glucose-Biosensor-to-be-Cleared-by-FDA-as-Over-the-Counter/default.aspx ↗
2. https://investors.dexcom.com/news/news-details/2024/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing/default.aspx ↗
3. https://www.medtechdive.com/news/dexcom-gen-ai-feature-stelo-cgm/735918/ ↗

Common questions

What is Dexcom?

Dexcom is an American multinational medical device company pioneering continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, the company's product line includes the Dexcom G6, G7, and Stelo glucose biosensors, with manufacturing facilities in Arizona, Malaysia, and Ireland. Dexcom is publicly traded on Nasdaq (DXCM) and is a component of the S&P 500 and Nasdaq-100.

What does Dexcom make?

Dexcom has 1 robot model on the DEPLOY registry: Stelo (Dexcom builds both physical robots and the AI that runs them).

Is Dexcom publicly traded?

Yes. Dexcom is publicly traded on public markets, per the DEPLOY registry.

Who competes with Dexcom?

On the DEPLOY registry, peer companies to Dexcom building in the same form factors include Samsung Electronics, Butterfly Network, Abbott, Apple.

Where is Dexcom headquartered?

Dexcom is headquartered in San Diego, California, USA.